Prosecution Insights
Last updated: November 10, 2026
Application No. 19/006,720

COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH OXIDATIVE STRESS

Non-Final OA §103§112§DP
Filed
Dec 31, 2024
Priority
Mar 29, 2012 — provisional 61/617,501 +11 more
Examiner
STEVENS, MARK V
Art Unit
1613
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Cxl Ophthalmics LLC
OA Round
1 (Non-Final)
65%
Grant Probability
Favorable
1-2
OA Rounds
9m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allowance Rate
575 granted / 879 resolved
+5.4% vs TC avg
Strong +42% interview lift
Without
With
+41.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
49 currently pending
Career history
949
Total Applications
across all art units

Statute-Specific Performance

§101
5.1%
-34.9% vs TC avg
§103
39.8%
-0.2% vs TC avg
§102
11.7%
-28.3% vs TC avg
§112
23.9%
-16.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 879 resolved cases

Office Action

§103 §112 §DP
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Formal Matters Claims 1-3 are cancelled. Claim 4-9 are pending and under examination. Priority The instant application claims priority to 18/607292 filed on 3/15/2025 (CIP); 17/986828 filed on 11/14/2022; 16/983,177 filed on 8/3/2020; 16/738735 filed on 1/9/2020; 16/137,114 filed on 9/20/2018; 15/335,146 filed on 10/26/2016; 14/387,803 filed on 9/24/2014; 14/275192 filed on 5/12/2014; PCT/US2013/034467 filed on 3/28/2013; US provisional applications 61/617339 filed on 3/29/2012 and 61/617,501 filed on 3/29/2012 and PCT/US2013/034187 filed on 3/27/2013. Claims 6 and 9 will be considered with the priority date of 03/27/2013 as this amount with teaching of NaCl (sodium chloride) is found in PCT/US2013/034187. Information Disclosure Statement The Information Disclosure Statements (IDS) filed on 4/28/2025 and 9/2/2026 have been considered by the examiner. Claim Objection Claim 6 is objected to for “a NaCl” which should be just NaCl. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 5-9 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 5 and 6 recites the limitation "the riboflavin solution" in without a prior recitation of “riboflavin solution” from claim 4. The composition of claim 4 cannot be presumed to be a solution as other compositions having pH values could be emulsions or suspensions. There is insufficient antecedent basis for this limitation in the claim. Claims 7-9 are indefinite as “the riboflavin is riboflavin-5’-phosphate” is not clear since “riboflavin” is a distinct compound from “riboflavin-5’-phosphate”. Instead claim 4 could provide the items in optional form, “wherein the riboflavin source is riboflavin, riboflavin-5’-phosphate or a salt thereof”. Then claims 7-9 can be amended accordingly to narrow the option to “riboflavin-5’-phosphate”. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 4-6 is/are rejected under 35 U.S.C. 103 as being unpatentable over Iseli et al (Journal of Refractive Surgery, 2011, volume 27, pages 195-201, in applicant IDS) and Horwath-Winter et al (Br J Ophthalm, 2005, volume 89, pages 40-44, in applicant IDS). Iseli teaches using 0.5% riboflavin with dextran and NaCl for stabilizing corneal cross-linking (abstract). This relates to treating the eye. Iseli provides for an NaCl concentration of 0.9% (abstract). Iseli does not teach the basic pH or the sodium iodide. Horwath-Winter teaches iodide iontophoresis for treating dry eye syndrome (abstract). Horwath-Winter teaches 0.5% sodium iodide solution as at a pH of 8.0, it is predominately negatively charged (Chemicals, page 41). One of the ordinary skill in the art at the time of instant filing would have included sodium iodide of Horwath-Winter into a formulation of Iseli as it also has properties beneficial to treating the eye so that one would achieve a formulation having corneal crosslinking ability while also reducing the occurrence of dry eye. Horwath-Winter provides 0.5% of sodium iodide and the pH of 8.0 for the purpose of maintaining iodide ion while Iseli provides for 0.5% riboflavin. The claim is to a composition, and thus, the intended use of corneal crosslinking is not a limitation to the structure of the composition itself. The references provide for delivery to eye and excipients for that purpose. In regard to stable, this is a broad limitation to various types of stability since the specification does not define it particularly. Since the prior art teaches formulations for use in treatment, they are expected to have some degree of stability. In regard to iodide breaking hydrogen peroxide, since Horwath-Winter provides for iodide ion (negative ion) formation, it will have this capability when used. Thus, there is a reasonable expectation of success in providing the claimed composition with a reasonable expectation of success. Claims 7-9 in addition to Claims 4-6 is/are rejected under 35 U.S.C. 103 as being unpatentable over Iseli et al (Journal of Refractive Surgery, 2011, volume 27, pages 195-201), Horwath-Winter et al (Br J Ophthalm, 2005, volume 89, pages 40-44) and Bottos et al (Arq Bras Oftalmol, 2011, volume 74, pages 348-351). Iseli and Horwarth-Winter teach the claims as discussed above. Iseli and Horwarth-Winter do not teach riboflavin-5-phosphate. Bottos teaches riboflavin treatment for collagen crosslinking in the cornea (abstract). Bottos teaches using riboflavin-5-phosphate for the procedure (abstract). One of ordinary skill in the art before the time of filing would have included riboflavin-5-phosphate as the riboflavin as this was known in the prior art (Bottos) to be used for this purpose. Therefore, there was a reasonable expectation of success in including riboflavin-5-phosphate into a composition motivated by Iseli and Horwarth-Winter to achieve an ophthalmic composition for that can be used for corneal crosslinking. Obviousness-Type Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO internet Web site contains terminal disclaimer forms which may be used. Please visit http://www.uspto.gov/forms/. The filing date of the application will determine what form should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claim 4-5 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-12 of US Patent 9555111. Although the claims at issue are not identical as the instant claims are to a composition and the claims of ‘111 are to a system where part of the system involves a like composition, they are not patentably distinct from each other because both the instant claims and the claims of ‘111 disclose a solution with overlapping amounts of sodium iodide and riboflavin. The claims of '111 are not closed to other components by use of "comprising" as the transition phrase. It is noted that the disclosure of ‘111 discloses thiosulfate, vitamin C and sodium bisulfate as reducing agents (paragraph 31), other concentrations (paragraph 30) and other additives (paragraph 31). Even though the claims of ’111 provide for a crosslinking system, they disclose the compositions of the instant claims. Therefore, the claims of the instant application and patent ‘111 overlap in scope. Claim 6-9 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-12 of US Patent 9555111 in view of Iseli (cited above) and Bottos (cited above). Although the claims at issue are not identical as the instant claims are to a composition and the claims of ‘111 are to a system where part of the system involves a like composition, they are not patentably distinct from each other because both the instant claims and the claims of ‘111 disclose a solution with overlapping amounts of sodium iodide and riboflavin. The claims of '111 are not closed to other components by use of "comprising" as the transition phrase. It is noted that the disclosure of ‘111 discloses thiosulfate, vitamin C and sodium bisulfate as reducing agents (paragraph 31), other concentrations (paragraph 30) and other additives (paragraph 31). Even though the claims of ’111 provide for a crosslinking system, they disclose the compositions of the instant claims. Note that iodide or sodium iodide would constitute a salt. ‘111 claims do not teach NaCl in the concentration listed. ‘111 claims do not teach riboflavin-5-phosphate. Iseli teaches using 0.5% riboflavin with dextran and NaCl for stabilizing corneal cross-linking (abstract). This relates to treating the eye. Iseli provides for an NaCl concentration of 0.9% (abstract). Bottos teaches riboflavin treatment for collagen crosslinking in the cornea (abstract). Bottos teaches using riboflavin-5-phosphate for the procedure (abstract). One of ordinary skill in the art before the time of filing would have included riboflavin-5-phosphate as the riboflavin as this was known in the prior art (Bottos) to be used for this purpose. One of ordinary skill in the art would also use compositions with amounts of NaCl of the claims based on teachings of Iseli for these types of compositions. Therefore, there was a reasonable expectation of success in including riboflavin-5-phosphate into a composition motivated by Iseli and ‘111 claims to achieve an ophthalmic composition for that can be used for corneal crosslinking. Claims 4-5 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-10 of US Patent 9566301. Although the claims at issue are not identical as the instant claims are to a composition and the claims of ‘301 are to a system where part of the system involves a like composition, they are not patentably distinct from each other because both the instant claims and the claims of ‘301 disclose a solution with overlapping amounts of sodium iodide and riboflavin. The claims of '301 are not closed to other components by use of "comprising" as the transition phrase. It is noted that the disclosure of ‘301 discloses thiosulfate, vitamin C and sodium bisulfate as reducing agents, concentrations, and other additives. Note that although the instant application was filed as a divisional, the applicant has again elected the composition of matter rather than the methods of using the composition. The claims of ‘301 are to a composition of matter. Claim 7 of ‘301 provides for promoting photochemical crosslinking and reducing oxidative stress. Therefore, a rejection under obviousness-type double patenting is appropriate in this situation. Therefore, the claims of the instant application and ‘301 overlap in scope. Claims 6-9 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-10 of US Patent 9566301 in view of Iseli and Bottos. Although the claims at issue are not identical as the instant claims are to a composition and the claims of ‘301 are to a system where part of the system involves a like composition, they are not patentably distinct from each other because both the instant claims and the claims of ‘301 disclose a solution with overlapping amounts of sodium iodide and riboflavin. The claims of '301 are not closed to other components by use of "comprising" as the transition phrase. It is noted that the disclosure of ‘301 discloses thiosulfate, vitamin C and sodium bisulfate as reducing agents, concentrations, and other additives. Note that although the instant application was filed as a divisional, the applicant has again elected the composition of matter rather than the methods of using the composition. The claims of ‘301 are to a composition of matter. Claim 7 of ‘301 provides for promoting photochemical crosslinking and reducing oxidative stress. Therefore, a rejection under obviousness-type double patenting is appropriate in this situation. ‘301 claims do not teach NaCl in the concentration listed. ‘301 claims do not teach riboflavin-5-phosphate. Iseli teaches using 0.5% riboflavin with dextran and NaCl for stabilizing corneal cross-linking (abstract). This relates to treating the eye. Iseli provides for an NaCl concentration of 0.9% (abstract). Bottos teaches riboflavin treatment for collagen crosslinking in the cornea (abstract). Bottos teaches using riboflavin-5-phosphate for the procedure (abstract). One of ordinary skill in the art before the time of filing would have included riboflavin-5-phosphate as the riboflavin as this was known in the prior art (Bottos) to be used for this purpose. One of ordinary skill in the art would also use compositions with amounts of NaCl of the claims based on teachings of Iseli for these types of compositions. Therefore, there was a reasonable expectation of success in including riboflavin-5-phosphate into a composition motivated by Iseli and ‘301 claims to achieve an ophthalmic composition for that can be used for corneal crosslinking. Claims 4-5 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of US Patent 10,729,716. Although the claims at issue are not identical as the instant claims are to a composition and the claims of ‘716 are to a system where part of the system involves a like composition, they are not patentably distinct from each other because both the instant claims and the claims of ‘716 disclose a composition with iodide, riboflavin and an ocular excipient and a basic pH. The claims of '716 are not closed to other components by use of "comprising" as the transition phrase. Note that although the instant application was filed as a divisional, the applicant has again elected the composition of matter rather than the methods of using the composition. The claims of ‘716 are to a composition of matter. Therefore, a rejection under obviousness-type double patenting is appropriate in this situation. Therefore, the claims of the instant application and ‘716 overlap in scope. Claims 6-9 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of US Patent 10,729,716 in view of Iseli and Bottos. Although the claims at issue are not identical as the instant claims are to a composition and the claims of ‘716 are to a system where part of the system involves a like composition, they are not patentably distinct from each other because both the instant claims and the claims of ‘716 disclose a composition with iodide, riboflavin and an ocular excipient and a basic pH. The claims of '716 are not closed to other components by use of "comprising" as the transition phrase. Note that although the instant application was filed as a divisional, the applicant has again elected the composition of matter rather than the methods of using the composition. The claims of ‘716 are to a composition of matter. Therefore, a rejection under obviousness-type double patenting is appropriate in this situation. ‘716 claims do not teach NaCl in the concentration listed. ‘716 claims do not teach riboflavin-5-phosphate. Iseli teaches using 0.5% riboflavin with dextran and NaCl for stabilizing corneal cross-linking (abstract). This relates to treating the eye. Iseli provides for an NaCl concentration of 0.9% (abstract). Bottos teaches riboflavin treatment for collagen crosslinking in the cornea (abstract). Bottos teaches using riboflavin-5-phosphate for the procedure (abstract). One of ordinary skill in the art before the time of filing would have included riboflavin-5-phosphate as the riboflavin as this was known in the prior art (Bottos) to be used for this purpose. One of ordinary skill in the art would also use compositions with amounts of NaCl of the claims based on teachings of Iseli for these types of compositions. Therefore, there was a reasonable expectation of success in including riboflavin-5-phosphate into a composition motivated by Iseli and ‘716 claims to achieve an ophthalmic composition for that can be used for corneal crosslinking. Claims 4-5 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-19 of US Patent 10,092,594. Although the claims at issue are not identical as the instant claims are to a composition and the claims of ‘594 are to a system where part of the system involves a like composition, they are not patentably distinct from each other because both the instant claims and the claims of ‘594 disclose a solution with overlapping amounts of sodium iodide and riboflavin. The claims of '594 are not closed to other components by use of "comprising" as the transition phrase. It is noted that the disclosure of ‘594 discloses thiosulfate, vitamin C and sodium bisulfate as reducing agents, concentrations, and other additives. Note that although the instant application was filed as a divisional, the applicant has again elected the composition of matter rather than the methods of using the composition. The claims of ‘594 are to a composition of matter. Therefore, a rejection under obviousness-type double patenting is appropriate in this situation. Therefore, the claims of the instant application and ‘594 overlap in scope. Claims 6-9 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-19 of US Patent 10,092,594 in view of Iseli and Bottos. Although the claims at issue are not identical as the instant claims are to a composition and the claims of ‘594 are to a system where part of the system involves a like composition, they are not patentably distinct from each other because both the instant claims and the claims of ‘594 disclose a solution with overlapping amounts of sodium iodide and riboflavin. The claims of '594 are not closed to other components by use of "comprising" as the transition phrase. It is noted that the disclosure of ‘594 discloses thiosulfate, vitamin C and sodium bisulfate as reducing agents, concentrations, and other additives. Note that although the instant application was filed as a divisional, the applicant has again elected the composition of matter rather than the methods of using the composition. The claims of ‘594 are to a composition of matter. Therefore, a rejection under obviousness-type double patenting is appropriate in this situation. ‘594 claims do not teach NaCl in the concentration listed. ‘594 claims do not teach riboflavin-5-phosphate. Iseli teaches using 0.5% riboflavin with dextran and NaCl for stabilizing corneal cross-linking (abstract). This relates to treating the eye. Iseli provides for an NaCl concentration of 0.9% (abstract). Bottos teaches riboflavin treatment for collagen crosslinking in the cornea (abstract). Bottos teaches using riboflavin-5-phosphate for the procedure (abstract). One of ordinary skill in the art before the time of filing would have included riboflavin-5-phosphate as the riboflavin as this was known in the prior art (Bottos) to be used for this purpose. One of ordinary skill in the art would also use compositions with amounts of NaCl of the claims based on teachings of Iseli for these types of compositions. Therefore, there was a reasonable expectation of success in including riboflavin-5-phosphate into a composition motivated by Iseli and ‘594 claims to achieve an ophthalmic composition for that can be used for corneal crosslinking. Claims 4-5 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-10 of US Patent 11497766. Although the claims at issue are not identical as the instant claims are to a composition and the claims of ‘766, they provide the composition with the riboflavin, the sodium iodide, concentrations ranges, basic pH and other limitations of the claim that obviate the claimed composition. Claims 6-9 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-10 of US Patent 11497766 in view of Iseli and Bottos. Although the claims at issue are not identical as the instant claims are to a composition and the claims of ‘766, they provide the composition with the riboflavin, the sodium iodide, concentrations ranges, basic pH and other limitations of the claim that obviate the claimed composition. ‘766 claims do not teach NaCl in the concentration listed. ‘766 claims do not teach riboflavin-5-phosphate. Iseli teaches using 0.5% riboflavin with dextran and NaCl for stabilizing corneal cross-linking (abstract). This relates to treating the eye. Iseli provides for an NaCl concentration of 0.9% (abstract). Bottos teaches riboflavin treatment for collagen crosslinking in the cornea (abstract). Bottos teaches using riboflavin-5-phosphate for the procedure (abstract). One of ordinary skill in the art before the time of filing would have included riboflavin-5-phosphate as the riboflavin as this was known in the prior art (Bottos) to be used for this purpose. One of ordinary skill in the art would also use compositions with amounts of NaCl of the claims based on teachings of Iseli for these types of compositions. Therefore, there was a reasonable expectation of success in including riboflavin-5-phosphate into a composition motivated by Iseli and ‘766 claims to achieve an ophthalmic composition for that can be used for corneal crosslinking. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARK V STEVENS whose telephone number is (571)270-7080. The examiner can normally be reached on M-F 9:00 am to 6:00 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Brian-Yong Kwon can be reached on (571)272-0581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARK V STEVENS/ Examiner, Art Unit 1613
Read full office action

Prosecution Timeline

Dec 31, 2024
Application Filed
Sep 30, 2026
Non-Final Rejection mailed — §103, §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778890
DEVELOPMENT OF A NEW FAMILY OF NANOCARRIERS DERIVED FROM NATURAL TETRAMERIC ACID LIPIDS
2y 5m to grant Granted Nov 03, 2026
Patent 12765573
SOFT CANDY WITHOUT FISHY TASTE OR ODOR AND PREPARATION METHOD THEREOF
2y 11m to grant Granted Oct 20, 2026
Patent 12751917
HYDROGELS AS ORAL DELIVERY DOSAGE FORMS, METHODS OF MAKING AND USING SAME
6y 1m to grant Granted Oct 06, 2026
Patent 12751959
CANNABIDIOL NANODRUG FORMULATIONS AND METHODS FOR USE OF THE SAME
3y 4m to grant Granted Oct 06, 2026
Patent 12751928
PROLONGED-RELEASE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF SULTIAME
2y 11m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+41.6%)
2y 8m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 879 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month